Ballinger brings 25+ years of biotech and startup leadership, scientific expertise and DE&I perspective to Council role
WATERTOWN, Mass. 6/15/2022 – Lyndra Therapeutics, a clinical-stage biopharmaceutical company working to make daily pills a thing of the past, today announced that President and Chief Operations Officer Jess Ballinger has been named to the National Small Business Association (NSBA) Leadership Council, joining other advocates from across the country as they work to promote the interests of small business to policymakers in Washington, D.C.
“I’m so excited about the progress our team at Lyndra has made to fundamentally change how people take their medicine, but I’m just as proud of the way we’re doing this: as a women-led company that truly embraces and understands the importance of diversity and inclusiveness,” stated Ballinger. “I’m honored to join the NSBA Leadership Council and to be able to bring my passion for science and D&I to this team of expert small-business leaders. As the backbone of American commerce, innovation and diverse ideas, small businesses need their voices heard in Congress – now more than ever as we continue to navigate the COVID-19 pandemic. I’m elated to be part of this important effort.”
NSBA is the nation’s oldest small-business advocacy organization and operates on a staunchly nonpartisan basis. Focused on tackling the many critical issues facing small business — including tax reform, regulatory restraint, healthcare costs and how access to capital will impact small business – the NSBA Leadership Council also provides valuable networking opportunities among small-business advocates and ensures small business has a seat at the table as Congress and regulators take up key proposals.
“I am proud to have Jess Ballinger as part of our Leadership Council,” stated NSBA President and CEO Todd McCracken. “She came to us highly recommended, and I look forward to our coordinated efforts for years to come.”
For more information on the NSBA Leadership Council, please visit www.nsba.biz.
About Lyndra Therapeutics
Lyndra Therapeutics is a clinical-stage biopharmaceutical company pioneering long-acting oral therapies. Lyndra is focused on commercializing therapies in central nervous system (CNS) disorders, which would most benefit from dramatically reduced dosing frequency. Lyndra’s lead product candidate, oral weekly risperidone (LYN-005), is being developed for the treatment of people living with schizophrenia and bipolar 1 disorder. The company is also committed to advancing its platform to tackle major public health and global health challenges, with therapies that include oral weekly levomethadone and oral weekly buprenorphine for opioid use disorder, a monthly oral contraception pill and oral biweekly ivermectin for malaria eradication. Since the founding of Lyndra, the company’s partners have included the Bill & Melinda Gates Foundation, the NIH, AbbVie and Gilead Sciences, Inc. Lyndra is headquartered in Watertown, MA and has a state-of-the-art GMP manufacturing facility in Lexington, MA.